FeesSafety
Pluang+

Phase 3 trial confirms ACARIZAX® safe and effective for dust mite allergy in China, approval filing set for 2027

Market News
19 Oct 2026, 16:29 WIB
GlobeNewsWire
View Source
Bullish
Phase 3 trial confirms ACARIZAX® safe and effective for dust mite allergy in China, approval filing set for 2027

ALK Abello's phase 3 trial in China showed that ACARIZAX®, a sublingual immunotherapy tablet for house dust mite allergy, is safe and effective after 24-28 weeks of treatment. The trial met its primary goal with significant symptom improvement and good tolerance among participants aged 12-65. These results align with previous global studies and support ALK's plan to file for regulatory approval in China in the first half of 2027, aiming to address the large under-treated allergy population there.

The phase 3 trial results for ACARIZAX® in China provide context for readers interested in health-sector developments. For readers following health stocks on Pluang as of Oct 19, 2026 20:02 WIB: out of 150 priced US health-sector stocks, 62 rose and 66 fell. Sanofi SA (SNY) traded at USD 39.90 with a 1-day change of -1.75% and a typical hold time of 94 days, contrasting with Summit Therapeutics Inc (SMMT) at USD 14.83 gaining 1.37% and held typically for 17 days, while Bristol-Myers Squibb Co (BMY) was priced at USD 58.95, down 1.34%, with a typical hold time of 92 days.

More News

Alphabet and Meta Platforms show strong growth but face distinct risks and valuation differences for 2027.

Alphabet and Meta Platforms show strong growth but face distinct risks and valuation differences for 2027.

Alphabet and Meta Platforms both demonstrate robust revenue growth driven by digital advertising and AI integration, with Alphabet focusing on search and cloud services, and Meta on social media engagement. Alphabet reported $471.1 billion revenue an...

Market News
Bullish
6 minutes ago
Mastercard offers steady growth and stability over Coinbase's volatile crypto exposure for 2027 investments.

Mastercard offers steady growth and stability over Coinbase's volatile crypto exposure for 2027 investments.

Coinbase Global and Mastercard represent two paths in finance: crypto infrastructure versus traditional payments. Coinbase's revenue is tied to volatile crypto trading, showing a 26.6% revenue decline and a net loss of $701.6 million in the past year...

Market News
Neutral
19 minutes ago
Dec 9 key for markets: Fed rate decision, Broadcom earnings, Micron buybacks set to impact stocks.

Dec 9 key for markets: Fed rate decision, Broadcom earnings, Micron buybacks set to impact stocks.

On December 9, three major events will influence the stock market: the Federal Open Market Committee (FOMC) is expected to raise interest rates, Broadcom will report its earnings with a focus on AI semiconductor revenue, and Micron will begin a large...

Market News
Neutral
29 minutes ago
Rising rates challenge Realty Income but its strong dividend and diversification offer resilience.

Rising rates challenge Realty Income but its strong dividend and diversification offer resilience.

Realty Income, a large net-lease REIT with over 15,500 properties, faces headwinds from rising interest rates which increase borrowing costs and pressure profits. However, the company has a strong track record of increasing dividends for 32 years and...

Market News
Bullish
44 minutes ago
DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

DICK'S Sporting Goods favored over Coupang for 2027 due to profitability and valuation despite Coupang's growth.

Coupang leads South Korea's e-commerce with strong logistics but faces losses and regulatory challenges, including a major data breach. DICK'S Sporting Goods, expanding through Foot Locker acquisition, shows strong profitability, a solid dividend, an...

Market News
Neutral
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App